A Phase 3 interventional study of Tezepelumab in Chronic Rhinosinusitis With Nasal Polyps, sponsored by AstraZeneca. Active, not recruiting at 41 sites in 9 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Rhinosinusitis with a site in Italy — 5 open to participants now, 9 under way, 4 of them phase 3. Rhinosinusitis · Italy.
Among the 14 studies in Rhinosinusitis with a site in Italy, this one is the 6th largest by enrollment of the 10 interventional ones that give a count, is one of 6 that started in 2024, is one of 5 in phase 3, and was the 7th registered.
252 studies on the registry are indexed under Rhinosinusitis; 70 are open to participants now.
Browse Rhinosinusitis studies →5 of the 14 studies in Rhinosinusitis with a site in Italy are open now. Recruiting first, the newest first:
The European Forum for Research and Education in Allergy and Airway Diseases · Sites in Italy, United States, Belgium and 8 more countries
Ages 18+
Eli Lilly and Company · Sites in Italy, United States, Argentina and 17 more countries
Ages 12+
Liaquat University of Medical & Health Sciences · Sites in Italy
Ages 18+
Liaquat University of Medical & Health Sciences · Sites in Italy
Ages 18+
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 34 Rhinosinusitis studies recruiting now, 15 (44%) set no upper age limit and 13 (38%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 181 is above the median of 74 across 177 interventional studies indexed under Rhinosinusitis.
Median enrollment 199 across the 10 interventional studies, 659 across the 4 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 14 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 5 studies filed under Rhinosinusitis — fewer than ten, so there is no comparison to draw.
6 of the studies in Rhinosinusitis with a site in Italy that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06706817Phase 3AstraZenecaA Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab | 2027-01-13 |
| NCT06338995Phase 3Eli Lilly and CompanyA Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) | 2027-05 |
| NCT04959448Regeneron PharmaceuticalsStudy Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP) | 2027-03-25 |
| NCT07800273Liaquat University of Medical & Health SciencesBactorinol® Nasal Spray With Reduced-Dose Mometasone in Adults With Chronic Rhinosinusitis | 2027-05-31 |
| NCT06970977The European Forum for Research and Education in Allergy and Airway DiseasesCRS Questionnaire Validation Project | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 14 studies in Rhinosinusitis with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objective of this study is to evaluate treatment outcomes of tezepelumab among participants with physician-determined surgery-eligible CRSwNP, with or without asthma.
Study details include:
This is a multicentre, open-label, single-arm, phase IIIb study is to describe changes from baseline in (1) participant-reported nasal congestion as evaluated by the nasal congestion score (NCS) and (2) participant-reported sino-nasal symptoms as evaluated by sino-nasal outcome test, 22 item (SNOT-22) following initiation of tezepelumab treatment.
Approximately 60 sites in 10 countries will enrol adult patients with physician determined surgery eligible CRSwNP.
The study is divided into 3 periods as described below:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The following age-specific requirements apply:
Exclusion Criteria:
Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the investigator and could:
History of cancer:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tezepelumab: Tezepelumab single dose subcutaneously injection.
Combination Product: Tezepelumab
IMP. Subcutaneous injection. Unit dose strengths 210 mg.
Also known as: TEZSPIRE®
Change from baseline in nasal congestion
Changes from baseline in participant-reported nasal congestion as evaluated by the nasal congestion score (NCS) as part of the nasal polyposis symptom diary (NPSD) following initiation of tezepelumab treatment.
Time frame: Week 24
Change from baseline in sino-nasal symptoms
changes from baseline in participant reported sino nasal symptoms as evaluated by sino nasal outcome test, 22 item (SNOT 22) total score following initiation of tezepelumab treatment.
Time frame: Week 24
Proportion of NCS responders
Proportion of NCS responders (minimal clinically important difference \[MCID\] from baseline = 1.0) at each collected timepoint.
Time frame: End of treatment - Week 24
Time to first response for NCS
Description of time to first response for NCS by analysing data at all collected timepoints.
Time frame: End of Treatment-week 24
Change from baseline in NCS
Change from baseline in NCS at each collected timepoint.
Time frame: Daily for the 2 weeks prior to Week 0 through end of treatment visit (EOT; Week 24).
Proportion of SNOT-22 responders
Proportion of SNOT-22 responders (MCID from baseline = -8.9) at each collected timepoint.
Time frame: Screening, Weeks 0, 2, 4, 8, 12, 16, 20, and 24.
Time to first response for SNOT-22
Description of time to first response for SNOT-22 by analysing data at all collected timepoints.
Time frame: Screening, Weeks 0, 2, 4, 8, 12, 16, 20, and 24.
Change from baseline in SNOT-22
Change from baseline in SNOT-22 at each collected timepoint.
Time frame: Screening, Weeks 0, 2, 4, 8, 12, 16, 20, and 24.
Change from baseline visit in nasal blockage (NB)
Change from baseline visit in NB measured by PNIF
Time frame: Weeks 0, 4, 12, and 24.
Change from baseline visit in NB
Change from baseline visit in NB measured by VAS-NB
Time frame: daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, 24.
Proportion of PNIF responders
Proportion of PNIF responders (MCID from baseline =20 L/min).
Time frame: Weeks 0, 4, 12, and 24.
Proportion of VAS-NB responders
Proportion of VAS-NB responders (MCID from baseline = -3.0) (in participants with VAS-NB ≥ 7 at baseline).
Time frame: daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, 24.
Time to first response for PNIF
Description of time to first response for PNIF by analysing data at all collected timepoints.
Time frame: Weeks 0, 4, 12, and 24
First response for VAS NB
Description of time to first response for VAS NB by analysing data at all collected timepoints (in participants with VAS-NB ≥ 7 at baseline).
Time frame: daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, 24.
Change from baseline in loss of smell score evaluated by UPSIT or Sniffin Sticks
Change from baseline in loss of smell score evaluated by UPSIT or Sniffin Sticks
Time frame: Weeks 0, 1, 2, 4, 8, 12, 16, 20, and 24
Change from baseline in loss of smell score evaluated by VAS-Taste
Change from baseline in loss of smell score evaluated by VAS-Taste
Time frame: daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24
Change from baseline in loss of smell score evaluated by VAS-Smell
Change from baseline in loss of smell score evaluated by VAS-Smell
Time frame: daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24.
Proportion of UPSIT responders
Proportion of UPSIT responders (MCID from baseline = 4)
Time frame: Weeks 0, 1, 2, 4, 8, 12, 16, 20, and 24.
Proportion of Sniffin sticks responders
Proportion of Sniffin sticks responders (MCID from baseline = 6)
Time frame: Weeks 0, 1, 2, 4, 8, 12, 16, 20, and 24
Proportion of VAS-Smell responders
Proportion of VAS-Smell responders (MCID from baseline = -3.0) (in participants with VAS-Smell ≥ 7 at baseline)
Time frame: daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24
Proportion of participants with a reduction in VAS-Taste score from baseline
Proportion of participants with a reduction in VAS-Taste score from baseline (in participants with VAS-Taste ≥ 7 at baseline)
Time frame: daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24.
Time to first response for UPSIT/Sniffin sticks
Time to first response for UPSIT/Sniffin sticks by analysing data at all collected timepoints.
Time frame: Weeks 0, 1, 2, 4, 8, 12, 16, 20, and 24
Time to first response for VAS Smell
Time to first response for VAS Smell by analysing data at all collected timepoints (in participants with VAS-Smell ≥ 7 at baseline).
Time frame: daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24
Time to first improvement in VAS-Taste
Time to first improvement in VAS-Taste by analysing data at all collected timepoints (in participants with VAS-Taste ≥ 7 at baseline).
Time frame: daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24.
Change from baseline in sleep as evaluated by PSQI total score
Change from baseline in sleep as evaluated by PSQI total score
Time frame: Weeks 0, 12, and 24.
Change from baseline in sleep as evaluated by SNOT-22 Sleep domain score
Change from baseline in sleep as evaluated by SNOT-22 Sleep domain score
Time frame: Screening, Week 0, Weeks 2, 4, 8, 12, 16, 20, and 24
Change from baseline in sleep as evaluated by VAS-Sleep
Change from baseline in sleep as evaluated by VAS-Sleep
Time frame: daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24
Proportion of PSQI responders
Proportion of PSQI responders (MCID from baseline = - 4.4)
Time frame: Weeks 0, 12, and 24
Proportion of SNOT-22 Sleep domain responders
Proportion of SNOT-22 Sleep domain responders (MCID from baseline = -2.9)
Time frame: Screening, Week 0, Weeks 2, 4, 8, 12, 16, 20, and 24
Proportion of participants with any improvement in VAS Sleep from baseline
Proportion of participants with any improvement in VAS Sleep from baseline (in participants with VAS-Sleep ≥ 7 at baseline)
Time frame: Daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24
Time to first response for PSQI
Time to first response for PSQI by analysing data at all collected timepoints.
Time frame: Weeks 0, 12, and 24.
Time to first response for SNOT-22 Sleep domain
Time to first response for SNOT-22 Sleep domain by analysing data at all collected timepoints.
Time frame: Screening, Week 0, Weeks 2, 4, 8, 12, 16, 20, and 24.
Time to first improvement for VAS-Sleep
Time to first improvement for VAS-Sleep by analysing data at all collected timepoints (in participants with VAS-Sleep ≥ 7 at baseline).
Time frame: daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24
Change from baseline in total NPS
Change from baseline in total NPS evaluated by nasal endoscopy.
Time frame: Screening, Weeks 2 and 24
Proportion of NPS responders
Proportion of NPS responders (MCID from baseline = 1.0) at Weeks 2 and 24.
Time frame: Screening, Weeks 2 and 24
Change from baseline in NPQ score
Change from baseline in NPQ score
Time frame: Weeks 0, 8, 12, and 24.
Proportion of NPQ responders
Proportion of NPQ responders (MCID from baseline = 7.0)
Time frame: Weeks 0, 8, 12, and 24
Time to first response for NPQ
Time to first response for NPQ by analysing data collected at each specified timepoint.
Time frame: Weeks 0, 8, 12, and 24.
Change from baseline in TSS
Change from baseline in TSS
Time frame: daily for the 2 weeks prior to Week 0 and through EOT (Week 24)
Proportion of TSS responders
Proportion of TSS responders (MCID from baseline = 4.0)
Time frame: daily for the 2 weeks prior to Week 0 and through EOT (Week 24)
Time to first response for TSS
Time to first response for TSS by analysing data at all collected timepoints.
Time frame: daily for the 2 weeks prior to Week 0 and through EOT (Week 24)
Change from baseline in NP severity
Change from baseline in NP severity as measured by VAS Overall symptoms
Time frame: daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24.
Proportion of VAS Overall symptom responders
Proportion of VAS Overall symptom responders (MCID from baseline = 2.5)
Time frame: daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24.
Time to first response for VAS-Overall symptom
Time to first response for VAS-Overall symptom by analysing data at all collected timepoints
Time frame: daily for the 2 weeks prior to Week 0 through the first 12 weeks of Treatment Period, and at Weeks 16, 20, and 24.
Proportion of participants who respond as 'well controlled' or 'completely controlled' NP symptoms to the NP control question
Proportion of participants who respond as 'well controlled' or 'completely controlled' NP symptoms to the NP control question
Time frame: Weeks 0, 4, 8, 12, 20, and 24.
Time to first response for NP control
Time to first response for NP control by analysing data at all collected timepoints.
Time frame: Weeks 0, 4, 8, 12, 20, and 24.
Endoscopy findings will be used to describe histological changes and describe CRSwNP visualization
Endoscopy findings will be used to describe histological changes and describe CRSwNP visualization from baseline to Week 24.
Time frame: Screening, Weeks 2 and 24
Change from baseline in blood eosinophil count (BEC), total serum IgE, specific IgE (including fungi/moulds [eg, Alternaria]), S. aureus enterotoxin IgE, and Fractional exhaled nitric oxide (FeNO; for asthma participants only)
Change from baseline in blood eosinophil count (BEC), total serum IgE, specific IgE (including fungi/moulds \[eg, Alternaria\]), S. aureus enterotoxin IgE, and Fractional exhaled nitric oxide (FeNO; for asthma participants only)
Time frame: Screening (for BEC and FeNO), Week 0 (for IgE and S. aureus enterotoxin IgE), Weeks 12 and 24
Change from baseline in WPAI-CRSwNP
Change from baseline in WPAI-CRSwNP
Time frame: Week 0 and Week 24
Proportion and annualised rate of primary care visits (all rates for CRSwNP-related and asthma-related).
Proportion and annualised rate of primary care visits (all rates for CRSwNP-related and asthma-related).
Time frame: 24 weeks pre-and post index (index = 1st tezepelumab dosing).
Change in incident rate of nasal infection comparing the post-index period versus the pre-index period
Change in incident rate of nasal infection comparing the post-index period versus the pre-index period (index = 1st tezepelumab dosing).
Time frame: 24 weeks pre- and post-index. (index = 1st tezepelumab dosing)
Change in proportion of participants with CRSwNP-related SCS use during the post-index period (24 weeks following tezepelumab first dose) versus the pre-treatment period (24 weeks prior to tezepelumab first dose)
Change in proportion of participants with CRSwNP-related SCS use during the post-index period (24 weeks following tezepelumab first dose) versus the pre-treatment period (24 weeks prior to tezepelumab first dose)
Time frame: 24-weeks pre- and post- index. (index = 1st tezepelumab dosing).
Change in average SCS daily dose during the post-index period versus dose at/closest to the index
Change in average SCS daily dose during the post-index period (24 weeks following tezepelumab first dose) versus dose at/closest to the index
Time frame: 24-weeks pre- and post- index. (index = 1st tezepelumab dosing).
Proportion of participants with the decision for CRSwNP surgery during the 24 weeks pre- and post-index and change in NP surgery proportion following tezepelumab initiation.
Proportion of participants with the decision for CRSwNP surgery during the 24 weeks pre- and post-index and change in NP surgery proportion following tezepelumab initiation.
Time frame: 24-weeks pre- and post- index. (index = 1st tezepelumab dosing).
Proportion of patients with CRSwNP exacerbation
Proportion of patients with CRSwNP exacerbation
Time frame: 24-weeks pre- and post-index (index = 1st tezepelumab dosing).
Change since baseline in Asthma Control Questionnaire 6 (ACQ-6) score
Change since baseline in Asthma Control Questionnaire 6 (ACQ-6) score
Time frame: Weeks 0 and 24.
ACQ-6 responder: proportion of participants with change since baseline in ACQ-6 of 0.5 or above
ACQ-6 responder: proportion of participants with change since baseline in ACQ-6 of 0.5 or above
Time frame: Weeks 0 and 24
Annualised asthma exacerbation rate
Annualised asthma exacerbation rate
Time frame: 24 weeks pre-and post-index (index = 1st tezepelumab dosing).
Change from baseline in Annualised asthma exacerbation rate
Change from baseline in Annualised asthma exacerbation rate
Time frame: 24 weeks pre-and post-index (index = 1st tezepelumab dosing).
Lung function (Forced expiratory volume in 1 second [FEV1]) (if available at site)
Lung function (Forced expiratory volume in 1 second \[FEV1\]) (if available at site)
Time frame: Weeks 0, 12 (lung function only) and 24.
Asthma-related SCS use (yes/no)
Asthma-related SCS use (yes/no)
Time frame: 24 weeks pre-and post-index (index = 1st tezepelumab dosing).
Proportion and annualised rate of urgent care (all rates for CRSwNP-related and asthma-related).
Proportion and annualised rate of urgent care (all rates for CRSwNP-related and asthma-related).
Time frame: 24 weeks pre-and post index (index=1st tezepelumab dosing)
Proportion and annualised rate of unplanned surgery (all rates for CRSwNP-related and asthma-related).
Proportion and annualised rate of unplanned surgery (all rates for CRSwNP-related and asthma-related).
Time frame: 24 weeks pre and post index (index=ist tezepelumab dosing)
Proportion and annualised rate of unplanned out participant visits (all rates for CRSwNP-related and asthma-related).
Proportion and annualised rate of unplanned out participant visits (all rates for CRSwNP-related and asthma-related).
Time frame: 24 weeks pre- and post index (index=1st tezepelumab dosing)
Proportion and annualised rate of emergency room visits (all rates for CRSwNP-related and asthma-related).
Proportion and annualised rate of emergency room visits (all rates for CRSwNP-related and asthma-related).
Time frame: 24 weeks pre-and post index (index=1st tezepelumab dosing)
Proportion and annualised rate of hospitalisations (all rates for CRSwNP-related and asthma-related).
Proportion and annualised rate of hospitalisations (all rates for CRSwNP-related and asthma-related).
Time frame: 24 weeks pre-and post index(index=1st tezepelumab dosing)
Asthma related SCS use as part of an exacerbation
Asthma related SCS use as part of an exacerbation
Time frame: 24 weeks pre-and post index(index=1st tezepelumab dosing)
Asthma related SCS duration of use
Asthma related SCS duration of use
Time frame: 24 weeks pre-and post index(index=1st tezepelumab dosing)
Asthma related SCS daily dose
Asthma related SCS daily dose
Time frame: 24 weeks pre-and post index(index=1st tezepelumab dosing)
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Jan 2027, 25 months after the start.
Of 24 phase 3 interventional studies under Rhinosinusitis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 37. This study's planned 25 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tezepelumab